新辅助化疗后腋窝淋巴结清扫的淋巴结阳性乳腺癌放疗对局部区域控制的影响:ACOSOG Z1071 临床试验结果
ACOSOG Z1071 试验纳入 2009 至 2011 年接受新辅助化疗的 cT0-4N1-2 乳腺癌女性,患者接受前哨淋巴结手术及腋窝淋巴结清扫,放疗由主治医生决定。术后及区域淋巴结放疗有降低局部区域复发的趋势,但未影响总生存、无病生存或乳腺癌特异性生存。
要点
- 病理完全缓解者局部区域无复发生存、远处无转移生存、乳腺癌特异性生存和总生存均优于残留病灶者。
- 三阴性乳腺癌局部区域复发率高于激素受体阳性乳腺癌(HR 5.91,95%CI 2.80-12.49)。
- 术后及区域淋巴结放疗有降低局部区域复发的趋势,但未影响总生存、无病生存或乳腺癌特异性生存。
核心结论
- 在新辅助化疗后放疗由主治医生决定的情况下,放疗与局部区域复发降低的趋势相关,但与总生存、乳腺癌特异性生存或疾病特异性生存无关。
- 三阴性乳腺癌与更高的局部区域复发率相关。
研究设计与样本
- ACOSOG Z1071 试验纳入 2009 至 2011 年接受新辅助化疗的 cT0-4N1-2 乳腺癌女性,患者接受前哨淋巴结手术及腋窝淋巴结清扫,放疗由主治医生决定。
主要发现
- 701 例 eligible 患者中,423 例(59.6%)行乳房切除术,277 例(40.4%)行保乳手术;新辅助化疗后 506 例(72.2%)有残留病灶,195 例(27.8%)达病理完全缓解。
- 三阴性乳腺癌相比激素受体阳性乳腺癌,局部区域复发率更高(HR 5.91,95%CI 2.80-12.49)。
- 术后及区域淋巴结放疗有降低局部区域复发的趋势,但未影响总生存、无病生存或乳腺癌特异性生存。
关键数值与推荐
- 三阴性乳腺癌局部区域复发 HR 5.91(95%CI 2.80-12.49)。
临床怎么用
- 对于新辅助化疗后淋巴结阳性并接受腋窝淋巴结清扫的乳腺癌患者,放疗由主治医生决定,放疗与局部区域复发降低的趋势相关,但未显示生存获益。
- 病理完全缓解者预后更佳,三阴性乳腺癌局部区域复发风险更高,临床决策时可参考这些因素。
局限性
- 放疗使用由主治医生决定,非随机分配,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Use of adjuvant radiation therapy (RT) after neoadjuvant chemotherapy (NAC) in node-positive breast cancer (BC) is highly variable. In ACOSOG Z1071, RT after NAC was used at the discretion of treating physicians. Herein, we report the impact of RT and pathologic response on locoregional recurrence (LRR) after NAC. METHODS AND MATERIALS: ACOSOG Z1071 enrolled women with cT0-4N1-2 BC treated with NAC from 2009 to 2011. Patients underwent sentinel node surgery and completion axillary lymph node dissection. The RT was at the discretion of the treating physicians. Patient outcomes were analyzed as a function of clinical-pathologic factors and use of RT. RESULTS: Of 701 eligible patients, mastectomy was performed in 423 (59.6%) and breast-conserving surgery in 277 (40.4%). After NAC, residual disease was observed in 506 (72.2%), and 195 (27.8%) had a pathologic complete response. Of the patients, 591 (85.3%) received adjuvant RT and 102 (14.7%) did not. Median follow-up was 5.9 years. Forty-three patients (6.1%) experienced LRR, 145 (20.7%) experienced distant metastasis, and 142 (20.4%) died. Patients with pathologic complete response had the best LRR-relapse-free survival (hazard ratio [HR], 0.32; 95% confidence interval, 0.12-0.81; P = .016), distant metastasis-free survival (HR, 0.31; 95% CI, 0.19-0.52; P < .0001), BC-specific survival (HR, 0.34; 95% CI, 0.19-0.59; P = .0001) and overall survival (HR, 0.39; 95% CI, 0.240-0.63; P = .001) compared to patients with residual disease after NAC. Patients with triple-negative BC had a higher LRR rate compared to those with hormone receptor-positive BC (HR, 5.91; 95% CI, 2.80-12.49). There was a trend toward lower LRR with the use of postmastectomy and regional nodal RT, but there was no impact on overall, disease-free, or BC-specific survival. CONCLUSION: In the ACOSOG Z1071 trial, in which the use of RT after NAC was at the discretion of the treating physicians, RT was associated with a trend toward decreased LRR. There was no association of RT with overall survival, BC-specific survival, or Disease Specific Survival. Triple-negative BC was associated with higher locoregional relapse rates.
引用
- Haffty BG, McCall LM, Ballman KV, et al. Impact of Radiation on Locoregional Control in Women with Node-Positive Breast Cancer Treated with Neoadjuvant Chemotherapy and Axillary Lymph Node Dissection: Results from ACOSOG Z1071 Clinical Trial. Int J Radiat Oncol Biol Phys. 2019. PMID: 31085287. doi:10.1016/j.ijrobp.2019.04.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。